290 related articles for article (PubMed ID: 7449384)
21. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis.
Pardthaisong T
J Biosoc Sci; 1984 Jan; 16(1):23-34. PubMed ID: 6230362
[TBL] [Abstract][Full Text] [Related]
22. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
23. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
24. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
[TBL] [Abstract][Full Text] [Related]
25. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
[TBL] [Abstract][Full Text] [Related]
26. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
[TBL] [Abstract][Full Text] [Related]
27. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
Westhoff C
J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
[TBL] [Abstract][Full Text] [Related]
28. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
29. Pregnancy after removal of Norplant implants contraceptive.
Affandi B; Santoso SS; Djajadilaga ; Hadisaputra W; Moeloek FA; Prihartono J; Lubis F; Samil RS
Contraception; 1987 Aug; 36(2):203-9. PubMed ID: 3123134
[TBL] [Abstract][Full Text] [Related]
30. Forearm bone density in users of Depo-Provera as a contraceptive method.
Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
[TBL] [Abstract][Full Text] [Related]
31. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
[TBL] [Abstract][Full Text] [Related]
32. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction.
Kongsayreepong R; Chutivongse S; George P; Joyce S; McCone JM; Garza-Flores J; Valles de Bourges V; de La Cruz DL; Perez-Palacios G; Rosseneu M
Contraception; 1993 Feb; 47(2):177-91. PubMed ID: 8449018
[TBL] [Abstract][Full Text] [Related]
33. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
[TBL] [Abstract][Full Text] [Related]
34. Long-term depot-medroxyprogesterone acetate and bone mineral density.
Tang OS; Tang G; Yip P; Li B; Fan S
Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083
[TBL] [Abstract][Full Text] [Related]
35. The association of depo-medroxyprogesterone acetate and breast cancer.
Greenspan AR; Hatcher RA; Moore M; Rosenberg MJ; Ory HW
Contraception; 1980 Jun; 21(6):563-9. PubMed ID: 7428364
[TBL] [Abstract][Full Text] [Related]
36. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
Jeppsson S; Gershagen S; Johansson ED; Rannevik G
Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
[TBL] [Abstract][Full Text] [Related]
37. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
Keder LM; Rulin MC; Gruss J
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
[TBL] [Abstract][Full Text] [Related]
38. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
[TBL] [Abstract][Full Text] [Related]
39. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user.
Dahlberg K
Int J Gynaecol Obstet; 1982 Feb; 20(1):43-8. PubMed ID: 6126406
[TBL] [Abstract][Full Text] [Related]
40. A study of adrenal corticol function and its reserve activity in long-acting injectable contraceptive users.
Amatayakul K; Petpoo W; Ratanawananukul N; Tanthayaphinant O; Tovanabutra S; Suriyanon V
Contraception; 1988 May; 37(5):483-92. PubMed ID: 2970367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
